CTRI/2020/09/027875进行中（未招募）4 期
A Prospective, Multicentric, Randomized, Open Label, Active Controlled Trial To Evaluate The Efficacy And Safety Of Sucralfate Administered Concomitant to a PPI Versus PPI alone in Gastro Esophageal Reflux Disorder
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Adult subjects in the age group 18-65, diagnosed with GERD i.e. Heartburn (defined as a burning sensation in the retrosternal area) with or without regurgitation (defined as the perception of flow of refluxed gastric content into the mouth or hypopharynx) with mild symptoms occurring on two or more days a week or moderate or severe symptoms occurring on one or more days a week
- •2. Able to understand and complete questionnaires, able to give written informed consent, and have access to a telephone
排除标准
- •1. Patients with alarm symptoms such as unintentional weight loss, progressive difficulty swallowing (dysphagia), iron deficiency anaemia, persistent coughing, laryngitis, pharyngitis and epigastric mass
- •2. Significant gastrointestinal obstruction, major gastric or oesophageal surgery (excluding appendectomy or cholecystectomy), oesophageal stricture or pyloric stenosis, extra oesophageal manifestations of reflux disease
- •3. Patients with erosive oesophagitis, Barretts oesophagus (greater than 3cm), Zollinger Ellison Syndrome, scleroderma, malignancy (other than non-melanoma skin cancers) present within the last 5 years, hypersensitivity to rabeprazole or esomeprazole or any PPI, or any other significant condition that, in the opinion of the investigator, could interfere with the patients participation or compliance in the study such as past or current history of alcohol or drug abuse, hepatic, renal, pulmonary, respiratory abnormalities, or who have participated in an investigational drug or investigational device study within 30 days prior to the baseline visit or who are expected to do so during the 4 week study period
- •4. Female patients who are currently pregnant or breast feeding, or who, in the opinion of the investigator, may become pregnant throughout the study
- •5. Use of histamine 2 receptor antagonists (H2RAs) within 7 days of randomization, anticholinergics, cholinergics, spasmolytics, opiates, sucralfate, prokinetics, antibiotics (in relation to H. pylori treatment) or bismuth compounds within 14 days of randomization
- •6. Known Human Immunodeficiency Virus (HIV) positive, Hepatitis B or C status.
研究者
相似试验
招募中
4 期
To Evaluate Efficacy and Safety of Fixed dose combination of Trypsin - Chymotrypsin Enzyme and Diclofenac OralTablet in comparison with Diclofenac oral Tablet in soft tissue injuriesCTRI/2017/10/010223Torrent Pharamceutical Ltd
已完成
3 期
A Phase 3 study to evaluate the Efficacy, Safety and Tolerability of fixed dose combination of Dapagliflozin 10 mg Gliclazide 60 mg SR tablet in Patients with Type 2 Diabetes Mellitus who are inadequately controlled on Metformin Monotherapy.CTRI/2023/01/049286Eris Life Sciences Limited244
已完成
4 期
A study on comparison of glargine plus glulisine with premixed insulin in type 2 diabetes patientsCTRI/2017/02/007861India Diabetes Research Foundation
尚未招募
3 期
A study to evaluate the Safety and Effectiveness of Tofacitinib Gel versus Minoxidil Solution in Treatment of Adult Male Patients with Androgenetic Alopecia.CTRI/2022/09/045412MACLEODS PHARMACEUTICALS LTD
招募中
3 期
A comparative Phase III clinical study of Insulin Glargine in Adults with Type 2 Diabetes.CTRI/2021/11/037994M J Biopharm Pvt Ltd